Literature DB >> 17300625

How much fat is necessary to optimize lumefantrine oral bioavailability?

Elizabeth A Ashley1, Kasia Stepniewska, Niklas Lindegårdh, Anna Annerberg, Am Kham, Al Brockman, Pratap Singhasivanon, Nicholas J White, François Nosten.   

Abstract

BACKGROUND: Artemether-lumefantrine (AL) is the only fixed, artemisinin-based combination antimalarial drug which is registered internationally and deployed on a large scale. Absorption of the hydrophobic lipophilic lumefantrine component varies widely between individuals and is greatly increased by fat coadministration; but patients with acute malaria are frequently nauseated and anorexic, making dietary advice difficult to comply with. The aim of this study was to describe the dose-response relationship between coadministration of fat and relative lumefantrine bioavailability, in order to determine the minimum amount of fat necessary to optimize absorption.
METHOD: We conducted a multiple crossover pharmacokinetic study in 12 healthy volunteers. This compared the area under the plasma concentration-time curve (AUC) for lumefantrine after administration of a single dose of AL in the fasting state given with 0, 10, 40, 150 and 500 ml of soya milk corresponding to 0, 0.32, 1.28, 4.8 and 16 g of fat. All volumes of milk supplements were tested in all subjects with a 3- to 4-week washout period in-between.
RESULTS: A dose-response relationship was demonstrated between the volume of soya milk administered and lumefantrine bioavailability. AL administration with soya milk increased the lumefantrine AUC more than five fold. The population mean estimated volume of soya milk required to obtain 90% of maximum effect (in terms of lumefantrine AUC) was 36 ml (corresponding to 1.2 g of fat).
CONCLUSIONS: Coadministration of artemether-lumefantrine with a relatively small amount of fat (as soya milk) was required to ensure maximum absorption of lumefantrine in healthy adult volunteers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17300625     DOI: 10.1111/j.1365-3156.2006.01784.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  63 in total

1.  Efficacy of artemether-lumefantrine in area of high malaria endemicity in India and its correlation with blood concentration of lumefantrine.

Authors:  Neena Valecha; Suman Mohanty; Prakriti Srivastava; Surya Sharma; Prajesh Tyagi; Yngve Bergqvist; Pascal Ringwald
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

2.  Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.

Authors:  Joel Tarning; Rose McGready; Niklas Lindegardh; Elizabeth A Ashley; Mupawjay Pimanpanarak; Benjamas Kamanikom; Anna Annerberg; Nicholas P J Day; Kasia Stepniewska; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.

Authors:  Sam Salman; Madhu Page-Sharp; Susan Griffin; Kaye Kose; Peter M Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

4.  Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.

Authors:  T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

5.  Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.

Authors:  Sam Salman; Madhu Page-Sharp; Kevin T Batty; Kaye Kose; Susan Griffin; Peter M Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

Review 6.  Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present.

Authors:  Carol Hopkins Sibley; Ric N Price
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-20       Impact factor: 4.077

7.  Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children.

Authors:  Catherine O Falade; Oluwatoyin O Ogunkunle; Hannah O Dada-Adegbola; Adegoke G Falade; Patricia Ibarra de Palacios; Philip Hunt; Mailis Virtanen; Ayoade M Oduola; Lateef A Salako
Journal:  Malar J       Date:  2008-11-27       Impact factor: 2.979

Review 8.  The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence.

Authors:  Zulfiqarali G Premji; Salim Abdulla; Bernhards Ogutu; Alice Ndong; Catherine O Falade; Issaka Sagara; Nathan Mulure; Obiyo Nwaiwu; Gilbert Kokwaro
Journal:  Malar J       Date:  2008-11-25       Impact factor: 2.979

Review 9.  Understanding the pharmacokinetics of Coartem.

Authors:  Abdoulaye Djimdé; Gilbert Lefèvre
Journal:  Malar J       Date:  2009-10-12       Impact factor: 2.979

10.  Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.

Authors:  Stephan Ehrhardt; Christian G Meyer
Journal:  Ther Clin Risk Manag       Date:  2009-10-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.